fbpx

U.S. Anti-Doping Agency (USADA)

Global DRO logo in whiteSearch Medications & Ingredients

U.S. Weightlifting Athlete Trevor Cuicchi Accepts Sanction for Anti-Doping Rule Violation

weightlifterUSADA announced today that Trevor Cuicchi, of Mesa, Ariz., an athlete in the sport of weightlifting, has accepted a nine-month sanction after testing positive for a prohibited substance from a contaminated dietary supplement.

Cuicchi, 22, tested positive for ostarine as the result of an out‐of‐competition urine sample he provided on June 14, 2018. Ostarine is a non-Specified Substance in the class of Anabolic Agents and prohibited at all times under the USADA Protocol for Olympic and Paralympic Movement Testing, the United States Olympic Committee National Anti-Doping Policies, and the International Weightlifting Federation Anti-Doping Rules, all of which have adopted the World Anti-Doping Code and the WADA Prohibited List.

Ostarine, also known as MK-2866 and Enobosarm, is a selective androgen receptor modulator (SARM) that is illegally sold in the United States and worldwide as a performance-enhancing substance. Ostarine is not approved by the U.S. Food and Drug Administration (FDA); it is not currently available as a prescription medication in any country; and its unauthorized use may carry serious side effects and is a threat to public health. Nonetheless, ostarine has been found as a declared and undeclared ingredient in many dietary supplements sold in the United States, which has prompted the FDA to issue warning letters to specific dietary supplement manufacturers stating that ostarine is an unapproved new drug and that selling the drug is in violation of the Federal Food, Drug, and Cosmetic Act. More information about the risks of ostarine can be found through a USADA athlete advisory.

During an investigation into the circumstances of the case, Cuicchi provided USADA with information about a supplement purchased and used prior to sample collection, which did not list ostarine or any known synonym on the Supplement Facts label. Detailed analysis subsequently conducted on the supplement by the WADA-accredited laboratory in Salt Lake City, Utah, confirmed the presence of ostarine in the product.

Cuicchi’s nine-month period of ineligibility began on June 14, 2018, the date his positive sample was collected. In addition, Cuicchi has been disqualified from competitive results obtained on and subsequent to June 14, 2018, including forfeiture of any medals, points and prizes.

In an effort to aid athletes, as well as support team members such as parents and coaches, in understanding the rules applicable to them, USADA provides comprehensive instruction on its website on the testing process and prohibited substances, how to obtain permission to use a necessary medication, and the risks and dangers of taking supplements (www.Supplement411.org) as well as performance-enhancing and recreational drugs. In addition, USADA manages a drug reference hotline, Global Drug Reference Online (www.GlobalDRO.com), conducts educational sessions with National Governing Bodies and their athletes, and distributes a multitude of educational materials, such as an easy-reference wallet card with examples of prohibited and permitted substances, a supplement guide, a nutrition guide, an athlete handbook, and periodic alerts and advisories.

Along with education and testing, robust anti-doping programs enable investigations stemming from tips and whistleblowers. USADA makes available a number of ways to report the abuse of performance-enhancing drugs in sport in an effort to protect clean athletes and promote clean competition. Any tip can be reported using the USADA Play Clean Tip Center, by email at playclean@usada.org, by phone at 1-877-Play Clean (1-877-752-9253) or by mail.

USADA is responsible for the testing and results management process for athletes in the U.S. Olympic and Paralympic Movement and is equally dedicated to preserving the integrity of sport through research initiatives and educational programs.


For more information or media inquiries, click here.

Scroll to Top